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Abstract
Background and Aims: Recent studies have shown the efficacy of autologous haematopoietic stem 
cell transplantation [HSCT] in severely refractory Crohn’s disease [CD] patients. HSCT is thought to 
eliminate auto-reactive cells; however, no specific studies of immune reconstitution in CD patients 
are available.
Methods: We followed a group of CD patients [n = 18] receiving autologous HSCT, with 50% of 
them achieving endoscopic drug-free remission. To elucidate the mechanisms driving efficacy, 
we monitored changes after HSCT in blood and intestine immune-cell composition. CD patients 
[n = 22] receiving anti-tumour necrosis factor [TNF]-α were included for comparison.
Results: Severe immune ablation followed by HSCT induced dramatic changes in both peripheral 
blood T and B cells in all patients regardless of the efficacy of the treatment. Endoscopic remission 
at week 52 following HSCT was associated with significant intestinal transcriptional changes. 
A  comparison of the remission signature with that of anti-TNFα identified both common and 
unique genes in the HSCT-induced response. Based on deconvolution analysis of intestinal biopsy 
transcriptome data, we show that response to HSCT, but not to anti-TNFα, is associated with an 
expansion of naïve B-cells, as seen in blood, and a decrease in the memory resting T-cell content. 
As expected, endoscopic remission, in response to both HSCT and anti-TNFα, led to a significant 
reduction in intestinal neutrophil and M1 macrophage content.
Conclusions: Peripheral blood immune remodelling after HSCT does not predict efficacy. In 
contrast, a profound intestinal T-cell depletion that is maintained long after transplant is associated 
with mucosal healing following HSCT, but not anti-TNFα.
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1. Introduction
Crohn’s disease [CD] is a chronic inflammatory disease of the intes-
tinal tract with considerable heterogeneity among affected patients 
in terms of disease phenotype and therapeutic responses. Despite 
the increase in the number of drugs approved for the management 
of CD, a significant percentage of patients remain unresponsive or 
lose response over time to treatments, and eventually require sur-
gery to control disease activity and/or complications. Nonetheless, 
in a fraction of these refractory patients, intestinal resection may not 
be possible due to disease location, extension or previous surgeries. 
For such patients, autologous haematopoietic stem cell transplanta-
tion [HSCT] represents a potential salvage therapy1 despite the risks 
associated with this procedure.2
Stem cell transplantation is an accepted therapy for haemato-
logical disorders, aplastic anaemia and immunodeficiencies. In the 
context of autoimmune diseases, the serendipitous benefits of trans-
plantation were initially reported in patients suffering from both 
immune-mediated diseases and haematological disorders. This led to 
trials that have shown the efficacy of autologous HSCT in treating 
an array of autoimmune diseases including refractory severe mul-
tiple sclerosis [MS],3,4 systemic lupus erythematosus,5 juvenile idi-
opathic arthritis,6 rheumatoid arthritis7 and, more recently, CD.1,8,9
Indeed, the ASTIC trial recently reported 50% mucosal healing 
at 1 year after HSCT9 in a population of patients refractory to all 
available therapeutic options. In addition, in the largest single-cen-
tre cohort study published to date, we showed that HSCT achieves 
drug-free endoscopic remission in 60% of patients at 1  year of 
follow-up.8 Although these data are uncontrolled, they allow the 
outcome of HSCT to be viewed in the context of reports of novel 
biological therapies. As an example, recently licensed anti-p40 anti-
bodies [ustekinumab] achieved a response to induction therapy in 
34% of patients refractory to anti-tumour necrosis factor [TNF]-α 
inhibitors; among this subset of initial responders, 53.1% achieved 
remission at 1 year, which represents just 18% of the whole popula-
tion enrolled in the study.10
The benefit of HSCT in autoimmunity is thought to originate 
from the ability of intense immune depletion to eliminate auto-
reactive cells regardless of their specificity. This would lead to de 
novo generation of immune cells that could re-establish tolerance,11 
although no objective evidence of this ‘resetting’ has been reported 
thus far. To explore this hypothesis, we monitored a group of 18 
CD patients for 1 year after receiving an autologous HSCT. We then 
compared immune reconstitution both in blood and in intestinal tis-
sue in patients who achieved endoscopic remission and those who 
did not at that same time point.
2. Material and Methods
Additional information is provided in the Supplementary Methods.
2.1. Patient population and follow-up
Autologous HSCT was considered for CD patients fulfilling the 
previously described inclusion criteria.2,8 Given that the mobiliza-
tion and conditioning protocols are intensely immunosuppressive, 
additional immunosuppression is avoided as it may potentially pose 
additional risks during the recovery phase. Anti-TNFα treatment 
and immunosuppressive drugs were stopped at least 4 and 2 weeks, 
respectively, before mobilization. The protocol was approved by the 
Catalan Transplantation Organization and by the local ethics com-
mittee. All patients provided written informed consent following 
extensive counselling. A total of 18 patients were recruited between 
March 2010 and September 2015. Patient characteristics at inclu-
sion are shown in Table  1. After discharge, patients were closely 
followed-up.2,8 In brief, Crohn’s Disease Activity Index [CDAI] and 
laboratory markers were assessed weekly during the first 30 days, 
and every 6  weeks thereafter. Colonoscopy and/or magnetic reso-
nance imaging were performed at baseline and at weeks 26, 52 
and 106 after transplant. The Simple Endoscopic Score for Crohn’s 
Disease [SES-CD] index was used at baseline and during follow-
up to assess endoscopic activity. Mucosal healing was defined as 
SES-CD < 7. Magnetic Resonance Index of Activity [MaRIA] was 
used at baseline and during follow-up in those patients in whom 
lesions could not be assessed by ileocolonoscopy. Data are shown in 
Supplementary Table 1. None of the patients included in this study 
received any immunosuppressive or biological treatment during the 
first year of follow-up, with the exception of patient 15 who con-
tinued to experience severe lesions 6  months after transplant and 
started anti-TNFα treatment at that time.
A second cohort comes from an observational prospective study, 
including CD patients who began treatment with an anti- TNFα 
antibody [infliximab or adalimumab] and were followed up for 
46  weeks. All patients underwent clinical and endoscopic evalua-
tion at weeks 0, 14 and 46. From April 2013 to September 2016, 
22 CD patients were included after obtaining written informed 
consent [Supplementary Table 2]. This study was approved by the 
Institutional Ethics Committee of the Hospital Clínic de Barcelona 
[Spain].
Controls [n = 19] were individuals undergoing colonoscopy for 
mild gastrointestinal symptoms or for colorectal cancer screening, 
who had a normal examination and no history of inflammatory 
bowel disease [IBD]. The mean age of this cohort was 53.25 years, 
ranging from 27 to 69 years; and 10/19 were males.
2.2. Sample collection
Blood samples were collected from patients receiving HSCT at 
baseline [pre-mobilization] and every 13  weeks after transplant 
for up to 1  year of follow-up. Blood was collected into PAXgene 
tubes and frozen at −20°C [PreAnalytiX; Qiagen]. A second blood 
sample was collected to obtain serum for antibody determination 
[Supplementary Methods]. An additional 40 mL of blood was used 
to isolate peripheral blood mononuclear cells [PBMCs]. PBMCs 
were cryopreserved until later use for cell population analysis.
Colonic and ileal biopsies were collected at the described time 
points from the involved areas of the intestine of CD patients and 
from the sigmoid colon or rectum of non-IBD controls. Biopsies 
were taken at routine colonoscopies, placed in RNAlater RNA 
Stabilization Reagent [Qiagen] and stored at −80°C until RNA 
isolation.
2.3. Microarrays
More detailed information on microarrays is given in Supplementary 
Methods. Transcriptomic analysis of whole blood RNA samples 
was performed at weeks 0, 13, 26 and 52. RNA was hybridized in 
Affymetrix chips Human Genome U219. Raw data were analysed 
using Bioconductor tools in R [v.3.2.3] employing linear models for 
microarray data [limma v.3.34.1] for differential expression analy-
sis, and adjusting for inter-patient differences [specifying a block 
argument for patient variable]. Pathway analysis was performed 
for those genes significantly regulated using Ingenuity Pathways 
Analysis [IPA, Ingenuity Systems, www.ingenuity.com]. Functional 
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analysis identified the biological functions that were most significant 
to the data set.
2.4. RNA sequencing
Barcoded RNA sequencing [RNAseq] libraries were prepared from 
500  ng total RNA using Illumina’s TruSeq stranded mRNA kit 
according to the manufacturer’s instructions. Libraries were subjected 
to paired-end sequencing [101  bp] on a HighSeq-4000 platform 
[Illumina]. Quality filtering was performed using cutadapt v.1.7.1; 
reads were then mapped against the human reference genome using the 
STAR aligner v.2.5.2a, and a STAR genome directory was created by 
supplying the Ensembl gtf annotation file [release GRCh38.10]. Read 
counts per gene were obtained using the RSEM program v.1.2.31 and 
the Ensembl gtf annotation file. Following analyses were performed 
using the R [v.3.2.3] statistical tool. The total number of expressed 
genes was 24  215. Differential expression analysis was performed 
with the limma v.3.34.5 and edger v.3.20.6 packages, adjusting for 
inter-patient differences [specifying a block argument for patient vari-
able]. To correct for multiple testing, the false discovery rate [FDR] 
was estimated using the method of Benjamini and Hochberg. A gene 
was considered differentially expressed when it was significant at 5% 
FDR and showed a fold-change [FC] higher than |1.5|.
2.5. Deconvolution
We used the online analytical platform CIBERSORT v.1.0112 to 
estimate the proportions of 22 immune cell types in biopsy sam-
ples. Analyses were done with 100 permutations, disabled quantile 
normalization and default statistical parameters. The results were 
filtered by a maximum p-value of 0.05.
2.6. Statistics
For two time-point comparisons, the Wilcoxon signed-rank test 
for paired samples was used. For two-group comparisons, the 
Mann–Whitney–Wilcoxon test was used. Graphs show the mean 
and standard error of the mean [SEM]. p-values ≤0.05 were consid-
ered statistically significant.
3. Results
3.1. Whole blood transcriptional analysis reflects 
changes in leukocyte populations following HSCT
We first analysed the transcriptional signature of peripheral blood 
by microarray analysis both before mobilization and at immune-
ablation [week 0], as well as at different time points [weeks 13, 26 
and 52] after HSCT in 14 CD patients from whom blood RNA sam-
ples were available [nine remitters]. A total of 199 genes were found 
to be significantly regulated [186 of them were down-regulated] at 
week 13 compared to week 0. The majority of these genes [95%] 
returned to baseline levels by week 52 [Figure  1A]. Interestingly, 
most of these genes were associated with T-cell functions [IPA analy-
sis, Figure 1B].
A second set of 50 genes [98% of them were up-regulated] 
showed a delayed modulation, which was significantly regulated at 
week 26 [but not at week 13] compared to week 0 [Figure 1C]. The 
majority of these genes [76%] remained up-regulated at week 52. 
Pathway analysis of this signature revealed the marked-up regula-
tion of B-cell-related functions [Figure 1D]. We compared the tran-
scriptional signatures in the blood of responders and non-responders 
at all time-points studied, but found no significant differences.
The depletion of T-cell-related genes at week 13 closely corre-
lated with changes in the whole T-cell populations detected in the 
peripheral blood of 18 CD patients receiving HSCT [Figure  1E]. 
Further analysis revealed that the decrease in total CD3+ lympho-
cytes at weeks 13 and 26 was primarily due to the sustained deple-
tion of CD4+ cells at that time [Figure 1E]. In agreement with the 
expansion of the B-cell transcriptional signature at week 26, we 
Table 1. HSCT cohort: patient characteristics at inclusion
All patients Remitters Non-remitters
n 18 9 9
Gender [male/female] 5/13 1/8 4/5
Age [years]a 29.28 ± 1.76 28.89 ± 1.96 29.67 ± 3.05
Age at diagnosisb
A1 [<16 years] 6 [33] 3 [33] 3 [33]
A2 [17–40 years] 12 [67] 6 [67] 6 [67]
A3 [>40 years] 0 [0] 0 [0] 0 [0]
Disease behaviourb
Inflammatory 13 [72] 7 [78] 6 [67]
Stenosing 1 [6] 1 [11] 0 [0]
Penetrating 4 [22] 1 [11] 3 [33]
Disease locationb
L1 [ileal] 0 [0] 0 [0] 0 [0]
L2 [colonic] 4 [22] 2 [22] 2 [22]
L3 [ileocolonic] 9 [50] 4 [45] 5 [56]
L1+L4 [ileal + upper disease] 1 [6] 1 [11] 0 [0]
L3+L4 [ileocolonic + upper disease] 4 [22] 2[22] 2[22]
Disease duration [years]a 10.33 ± 1.26 9.11 ± 1.66 11.56 ± 1.90
CDAIa 268.38 ± 25.13 258.30 ± 23.58 278.46 ± 45.85
SES-CDa 22.73 ± 1.90 21.14 ± 2.32 24.13 ± 3.04
Mutated NOD2 [Y/N] 2/16 1/8 1/8
CDAI, Crohn’s Disease Activity Index; SES-CD, Simple Endoscopic Score for Crohn’s Disease.
aMean ± SEM.
bn [%].















































































Figure 1. Transcriptional blood signatures following HSCT reveal changes in T and B cells. [A,C] Heatmap representation of microarray expression of top genes 
regulated at week 13 [A] or week 26 [C] compared to week 0. Each row shows one individual probe and each column an experimental sample. High expression 
levels are shown in red and low expression levels in green. An unsupervised hierarchical cluster method, using a Pearson distance and average linkage method, 
was applied for each gene classification. [B,D] Polar graphs showing the top functions identified by ingenuity pathways analysis [IPA] for the genes significantly 
regulated at week 13 [B] and week 26 [D]. Results are shown graphically as a negative logarithm of the probability score [the most statistically significant 
pathways have the highest value in the graph]. [E] Absolute numbers (per µL) of blood CD3+, CD4+ and CD8+ cells [mean ± SEM] at baseline [W0] and after 
haematopoietic stem cell transplantation [HSCT] in Crohn’s disease patients [n = 18]]. [F] Absolute numbers of blood CD19+ [mean ± SEM] at baseline [W0] and 
after HSCT in CD patients [n = 18]. *p < 0.05, **p < 0.01, ***p < 0.001; significant by Wilcoxon signed-rank paired test.
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observed a trend towards higher B-cell numbers in peripheral blood 
at week 52 after HSCT compared to baseline [Figure 1F]. However, 
this increase in total B-cell numbers was not statistically significant. 
Taken together these results show, as expected, a profound remodel-
ling of the immune cell population after HSCT.
3.2. Naïve and effector/memory T and B cells 
repopulate the peripheral compartment with 
different dynamics following HSCT
Within the T helper [CD3+CD4+] and B [CD19+] cell compartments, 
we used different cell-surface markers to identify naïve and memory 
populations by flow cytometry [Figure  2]. At week 13 following 
transplant, the total number of naïve CD4+CD45RA+ cells was sig-
nificantly reduced compared to week 0 [mean reduction of 96%; 
Figure 2A; p = 1 × 10−4]. CD45RO+ cells were also reduced [mean 
reduction of 58%; p = 2 × 10−4], although not to the same extent as 
the CD45RA+ compartment. Despite the marked decrease of naïve 
CD4+ cells, this subset was recovered by 1 year following HSCT. In 
contrast, CD4+CD45RO+ cells remained significantly low at week 52 
compared to baseline [p = 0.029; Figure 2A], showing that HSCT 
has a deep and sustained effect on T helper cell populations.
Unlike T cells, at the time points studied, the proportion of 
CD27− naïve B cells increased in peripheral blood following HSCT 
[mean increase of 49%, 70% and 154% at weeks 13, 26 and 52, 
respectively; Figure 2B]. This increase was statistically significant at 
1 year after transplantation [p = 3 × 10−2; Figure 2B], in agreement 
with the trend shown by transcriptional analysis [Figure 1C and D]. 
In contrast, activated CD27+ B cells were significantly reduced at 
weeks 13 and 26 [p  = 7 × 10−3 and 0.015, respectively] and fully 
recovered by week 52 [Figure  2B]. These data suggest that the 
increase we observed in the transcriptional B-cell signature in blood 
probably resulted from an expansion in the naïve B-cell compart-
ment following HSCT.
3.3. Changes in peripheral blood populations are 
not related to the control of CD activity after HSCT
Fifty per cent of our patient cohort achieved endoscopic drug-
free remission that was maintained up to 1  year after HSCT 
[Supplementary Table  1]. As shown in Supplementary Figure  1, 
both groups of patients showed comparable changes in cell subsets, 
including CD3+, CD4+, CD8+ and CD19+ subpopulations, follow-
ing immune ablation and during reconstitution. In agreement with 
this observation, the following whole blood transcripts underwent 
significant changes following HSCT that were comparable in all 
patients regardless of the protocol’s efficacy at all time points exam-
ined: those expressed by naïve T cells [including recent thymic emi-
grants], CCR7 and PTK7; IL7R and CD28 genes, both expressed by 
T cells, and largely by effector memory cells; CD40LG, up-regulated 
by activated T cells; and the B-cell-related genes CD79A and IGHD 
[Figure 3]. These data suggest that the lack of efficacy of HSCT may 
be unrelated to the overall measures of immune ablation used in 
our study.
3.4. IgG levels in serum remain unchanged after 
HSCT in CD patients
HSCT impacts the B-cell population in the blood, which may impact 
antibody production. Hence, we measured changes in serum anti-
body concentrations following HSCT. Total serum IgA and IgM 
were significantly decreased in patients following HSCT, while the 
concentration of total IgG remained unchanged up to 1 year after 
immune ablation [Figure 4A]. IgG levels against tetanus toxoid [TT] 
and five other vaccines were measured in serum [Figure  4B and 
Supplementary Figure 2]. For TT, patients are re-vaccinated about 
6  months after transplant, and hence specific antibodies surged 
at week 52 [Figure  4B]. We also measured IgG anti-Saccharomy-
ces cerevisiae antibodies [ASCAs]13 in the same group of patients 
[Figure 4C]. About 50% of patients presented ASCA levels above the 
established normal threshold [see Supplementary Methods] at week 
0. Changes in ASCAs after transplant varied markedly at the indi-
vidual level. Remarkably, for those patients with detectable ASCA 
levels before transplant, a decrease in ASCAs following HSCT did 
not correlate with disease improvement [Supplementary Figure 2]. 
We also measured IgG concentrations against Escherichia coli flagel-
lin proteins [Fla2, FlaX] and a predicted lipoprotein [YidX], both 
bacterial proteins previously associated with CD,14,15 and obtained 
similar results [Supplementary Figure 2]. These results suggest that 
while B cells and antibody responses are impacted by HSCT, these 
parameters are not correlated to treatment efficacy.
3.5. Transcriptional analysis of the intestine reveals 
differences between the signatures of remission 
induced by HSCT and anti-TNFα treatments
Biopsies for RNAseq analysis were taken whenever possible from the 
involved mucosa [colonic and/or ileal] of patients undergoing HSCT 
at different time points [Supplementary Table  3]. Given that the 
transcriptomic signatures of colonic and ileal mucosa are markedly 
different [see Supplementary Figure 3], as well as the fact that the 
majority of patients had colonic disease [Table 1 and Supplementary 
Table 3], we limited our analysis to the colonic signatures for the 
purpose of this study. Differential gene expression analysis was per-
formed between week 0 and different time points [weeks 26 and 52] 
after HSCT. In remitters [n = 8], a total of 1504 protein-coding genes 
were found to be significantly regulated [1189 of them were down-
regulated] at week 26 compared to week 0. At week 52, the number 
of protein-coding genes significantly regulated from baseline reached 
2099 [1730 down-regulated] [Figure 5A]. A common signature con-
taining 1043 genes was significantly regulated at both time points 
[Figure 5B shows a heatmap representation of the top 100 regulated 
common genes]. Pathway analysis revealed significant regulation of 
innate and acquired immune cell activation and recruitment, and 
cytokine production, amongst others [Figure 5C]. Upstream regula-
tor analysis showed the significant regulation of several key media-
tors in those patients in remission after HSCT [Figure 5D]. Cytokines 
such as TNF-α, interferon gamma [IFNγ], interleukin 1 alpha and 
beta [IL-1α, IL-1β], IL-17A, IL-6, and transforming growth factor 
beta [TGFβ]; transcriptional factors such as nuclear factor kappa 
beta [NF-ΚB], STAT1 and 3, hypoxia-inducible factor-1 [HIF-1] and 
interferon regulatory factor 1[IRF1]; or enzymes such as prostaglan-
din synthase 2 [PTFS2] and transglutaminase 2 [TGM2] were all 
predicted to be upstream regulators of those pathways found to be 
significantly inhibited 1 year after HSCT.
We next compared the signatures of endoscopic remission 
obtained following HSCT with those of remission induced by anti-
TNFα treatment. To that end, RNAseq analysis of biopsies was per-
formed in a cohort of patients evaluated at baseline and at weeks 14 
and 46 following anti-TNFα. Differential gene expression analysis of 
endoscopic remission at 46 weeks compared to baseline [pre-treat-
ment] showed significant regulation of 1820 genes. In total, 43% of 
this gene signature [789 genes, Figure 6A, Supplementary Table 4] 
was also regulated during remission following HSCT. Moreover, 
58% of the 2099 genes that changed [FDR  <  0.05; FC  >  1.5] at 
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week 52 by HSCT were also regulated, but only when uncorrected 
by multiple comparisons [nominal p value  <  0.05, |FC|  >  1.5] in 
anti-TNF-induced remission [Figure 6A]. Nonetheless, we observed 
a large number of genes [882] whose expression was exclusively 
regulated in remitters of the HSCT cohort. Among these HSCT-only 
regulated signature genes, we observed the significant down-regula-
tion of T-cell-related transcripts [i.e. CD3E, CD28, CD3G, CD4]. 
Indeed, IPA revealed the marked inhibition of canonical pathways 
A
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Figure 2. Differential recovery of blood naive and memory cells after autologous haematopoietic stem cell transplantation [HSCT] in Crohn’s disease patients. 
[A] Dot plots representing naïve [CD45RA+] and memory/activated [CD45RO+] compartments within CD4+ T cells at baseline [W0] and after HSCT [W13, W26 
and W52]. Data are from one representative patient. Below, the mean ± SEM is represented for all patients included at all time points [n = 18]. [B] Dot plots 
representing naïve [CD27–] and memory [CD27+] CD19+ B-cell subsets at baseline [W0] and after HSCT [W13, W26 and W52]. Data are from one representative 
patient. The mean ± SEM for the naïve and memory B-cell absolute numbers is represented [n = 18]. *p < 0.05, **p < 0.01, ***p < 0.001; significant by Wilcoxon 
signed-rank paired test.
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involving T effector functions [Figure 6B, Supplementary Table 5], 
suggesting that either the number of T cells or their degree of activa-
tion was severely diminished in HSCT-induced remission.
Comparison of genes regulated at 1 year of follow-up compared 
to baseline in anti-TNFα and HSCT shows a very low number of 
common genes in the non-responder population; only 26 out of the 
over 1600 regulated [FDR < 0.05] after HSCT were also changed by 
anti-TNFα [Supplementary Figure 4].
3.6. Immune cell deconvolution analysis reveals 
unique changes in patients responding to HSCT 
treatment compared to anti-TNFα
In light of the differences in the transcriptomic remission signa-
tures between anti-TNFα and HSCT treatments, we then analysed 
changes in the proportions of immune cells in the intestinal mucosa 
by CIBERSORT deconvolution analysis on the available biopsy 
RNAseq data. In both cohorts a subset of samples from non-IBD 
controls were also sequenced side-by-side for comparison.
We observed a significant increase of ‘naïve B cells’ at 6 months 
and 1 year following HSCT [Figure 7A] that seemed to closely paral-
lel the expansion observed in peripheral blood [Figure 1]. In addi-
tion, patients responding to HSCT exhibited a significant decrease 
in the ‘T cell memory resting’ subset [Figure 7B]. None of the anti-
TNFα-treated patients, regardless of response, showed comparable 
changes in these lymphocyte subsets.
Naïve B cells that are expanded up to 1 year following transplant 
return to pre-transplant levels at 2 years [week 106] of follow-up 
[Figure 7A]. In contrast, the decrease in the T-cell signature remains 
constant even up to 2 years after HSCT [Figure 7B]. Hence, decon-























































































Figure  3. Blood transcriptional analysis of selected T- and B-cell-expressed genes following autologous haematopoietic stem cell transplantation [HSCT]. 
Relative mRNA expression [mean ± SEM] of CCR7 and PTK7 [A], IL7R, CD40LG, and CD28 [B], and CD79A and IGHD [C] in whole blood of ten healthy non-IBD 
controls and 18 patients with Crohn’s disease [CD] undergoing HSCT at baseline [W0] and after HSCT [W13, W26, W52]. Gene expression in CD patients is 
shown for remitters and non-remitters separately. Remission to HSCT is defined as drug-free endoscopic remission at W52. *p < 0.05, **p < 0.01, ***p < 0.001; 
significant by Wilcoxon signed-rank paired test.
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T-cell mucosal compartments in patients in remission after HSCT, 
but not in those responding to anti-TNFα.
In contrast, when we looked at innate cells that are abundant in 
the inflamed mucosa of patients with active CD, we observed a sig-
nificant decrease of M1 macrophages and neutrophils. This occurred 
in both the HSCT and the anti-TNFα responding cohorts, correlat-
ing with endoscopic remission in both groups of patients [Figure 7C, 
D]. Taken together, these deconvolution results suggest that changes 
in both the B- and the T-cell mucosal compartments are not altera-
tions common to a generalized control of inflammation, but are 
rather unique to HSCT therapy.
To better characterize the changes in the T-cell subsets follow-
ing HSCT or anti-TNFα, we compared the expression of a selec-
tion of T-cell-related [Figure 8A–C] and myeloid-related [Figure 8D] 
transcripts as measured by RNAseq in both cohorts of patients. 
While expression of the neutrophil or macrophage markers CXCL9, 
CXCL10 and CD16B was significantly regulated in anti-TNF- and 
HSCT-responding patients [but not in the non-remitter groups] 
[Figure  8D], the T-cell markers CD3E, CD28 and CD40LG, as 
well as the T-resident memory marker [TRM] marker ITGA1 were 
significantly regulated only in the HSCT-responding cohort. Two 
other TRM receptors, CD69 and ITGAE, tended to decrease in the 
HSCT-remitting group, although this was not statistically significant 
[Figure  8B]. Remarkably, expression of activated effector T cells 
such as S1PR1, IL2RA and CTLA4 were significantly regulated 
in all patients who achieved an endoscopic response regardless of 
treatment option [Figure  8C]. Overall, our analysis suggests that 
endoscopic remission in anti-TNFα- or HSCT-responding patients 
is associated with a significant decrease in neutrophils, M1 mac-
rophages and activated T-effector cell markers. In contrast, we pro-
pose that HSCT has a profound effect on a subset of memory resting 
and potentially resident T cells that correlates with response to this 
therapeutic strategy. HSCT seems to markedly decrease total T-cell 
content in the mucosa of patients who achieve remission.
4. Discussion
The mechanisms that lead to the control of the dysregulated immune 
response following autologous HSCT are still not entirely clear. The 
accepted hypothesis is that the conditioning regime eliminates com-
mitted pathogenic lymphocyte clones, leading to de novo generation 
of immune cells that re-establish tolerance.16,17 Indeed, autologous 
HSCT has been shown to remodel the peripheral immune system, 
as evidenced by the regeneration of naïve B cells,11,18 thymic reac-
tivation,11,19–21 renewal of the T-cell receptor repertoire11,19,21 and 
the regeneration of regulatory T cells [Tregs]22,23 in the context of 
various immune diseases. Nonetheless, there are almost no specific 

























































Figure 4. IgG antibody levels in serum remain unchanged after autologous haematopoietic stem cell transplantation [HSCT] in Crohn’s disease patients. [A] 
Serum IgG, IgA and IgM concentrations [g/L; mean ± SEM] at baseline [W0] and after HSCT [W13, W26 and W52] in Crohn’s disease patients [n = 18]. Dotted line 
represents the serological protection level. *p < 0.05,  ***p < 0.001, ****p < 0.0001; significant by Wilcoxon signed-rank paired test. [B] Anti-tetanus toxoid [TT] 
antibodies [U.I./mL] detected by ELISA in patient serum at baseline [W0] and after HSCT [W13, W26 and W52]. Dotted line represents the serological protection 
level. [C] Serum anti-ASCA IgG antibodies at baseline [W0] and after HSCT [W13, W26 and W52]. Values represent extinctions at an optical density [O.D.] at 
620 nm obtained by ELISA. The dotted line represents the threshold established for seroreactivity [mean O.D.] in a group of healthy controls.












































































































Figure 5. Transcriptional intestinal signatures following HSCT reveal significant changes after HSCT. [A] Volcano plot representation of transcriptional changes in 
biopsies from patients in remission at week 52 compared to week 0. The log2[fold change] is shown along the x-axis and the −log10[corrected p-value] along the 
y-axis. Differentially expressed genes that reach significance [considered as corrected p < 0.05 and |FC|>1.5] are shown in colour [downregulated genes at week 
52 in green and upregulated genes in red]. [B] Heatmap representation of RNAseq expression of the top 100 genes significantly regulated at week 52 [that were 
also regulated at week 26] compared to week 0. Each row shows one gene and each column an experimental sample. High expression levels are shown in red and 
low expression levels in green. An unsupervised hierarchical cluster method, using a Pearson distance and average linkage method, was applied for each gene 
and sample classification. [C] Polar graph showing the top canonical pathways identified by IPA significantly regulated in remission at week 52 compared to week 
0. Results are shown graphically as a negative logarithm of the probability score [the most statistically significant pathways have the highest value in the graph]. 
[D] Bar plot showing the activation z-score of the top upstream regulators at week 52 in patients in endoscopic remission compared to week 0 found by IPA.
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autologous HSCT. A study from Clerici and collaborators did ana-
lyse peripheral immune changes in a cohort of seven CD patients 
undergoing autologous HSCT.24 In particular, the authors reported 
variations in the percentage of peripheral blood monocytes that 
produced TNFα and IL-10 at 6 and 12  months after autologous 
HSCT. In a subset of three of four patients defined as ‘full respond-
ers’ [patients who achieved endoscopic remission 6  months after 
transplant], they observed a transient increase in the percentage of 
circulating Treg cells during the first 6 months. Except for this lim-
ited characterization, no study to date has monitored the immune 
changes that take place in peripheral blood of CD patients receiving 
autologous HSCT. Furthermore, to our knowledge no data are avail-
able on the cellular and molecular changes that take place in the 
mucosa of these patients.
Our data clearly show that 3 months after severe immune abla-
tion and HSCT, the peripheral blood CD4+ T-cell compartment 
remains compromised, while the CD8+ T- and the B-cell subsets have 
completely recovered. Moreover, and in agreement with the existing 
literature,25 naïve CD4+ T cells remain almost completely depleted 
at the 3-month follow-up time point, but then recover to baseline 
levels by 1 year after transplant. This supports the notion that CD 
patients reconstitute the naïve T-cell compartment through mecha-
nisms of homeostatic proliferation and/or thymic output. In contrast 
to the naïve compartment, circulating memory T cells, while signifi-
cantly reduced compared to baseline at week 13, are not completely 
depleted at that time, suggesting that memory clones may survive 
chemotherapy or may be reintroduced in the graft. Despite this par-
tial apparent persistence, the CD4+ memory compartment showed 
a delayed recovery, in agreement with the existing literature.26 On 
the other hand, CD8+ cells rely mostly on the peripheral expansion 
of mature cells, and not on thymic function, and as we confirm here 
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Figure 6. HSCT exclusive remission-induced gene signature is related to down-regulation of T-cell canonical pathways. [A] Venn diagram showing the number of 
genes that are differentially expressed in CD-remitting colonic mucosa at week 52 after HSCT or week 46 after anti-TNF treatment compared to their respective 
baseline expression values. Genes are classified based on their significance: FDR < 0.05 or p < 0.05. About 40% of the genes [882 transcripts] within the HSCT-
induced signature were not changed by anti-TNFα. [B] Polar plot representing the top six pathways significantly regulated in the HSCT-induced signature that 
is not regulated by anti-TNF. The negative logarithm of the probability score [the most statistically significant pathways have the highest value in the graph] for 
each pathway is represented.
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replenishment of the CD4 and CD8 compartments after HSCT has 
also been observed in MS patients.28
The rapid recovery and later expansion of the B-cell compart-
ment we observed after HSCT was also in agreement with previous 
findings11; however, the persistence of IgG antibody titres was unex-
pected. Previous studies have shown a decrease in circulating immu-
noglobulins following high-dose chemotherapy and autologous 
CD34+ reconstitution,29 with serum IgM and IgA levels still signifi-
cantly decreased 9 months after reconstitution. Indeed, we observed 
a significant decrease in serum IgA and IgM immunoglobulins at 
6 and 12 months of follow-up. This reduction, however, was also 
detected in non-remitters. On the other hand, IgG levels remained 
unchanged regardless of the transplant’s efficacy, and protection 
towards common vaccines based on antibody serum levels was not 
lost after HSCT, in contrast to what has been previously reported.11 
It is important to note that much of the evidence on antibody titres 
after transplant is based on patients subject to more intense con-
ditioning regimes,29 raising the possibility that the less aggressive 
protocol used for immune-mediated diseases does not require mas-
sive re-immunization afterwards. Nevertheless, this needs to be con-
firmed in a larger patient cohort.
Therefore, our study shows that monitoring the depletion and 
recovery of the peripheral immune compartment after HSCT provides 
a measure of the extent of the immune depletion, but does not cor-
relate with the response [endoscopic remission] to the HSCT therapy.
Hence, we focused our analysis on the intestinal tissue in areas 
of active inflammation at baseline, and compared the transcrip-









































w0 w14 w46 w0 w14 w46
0.4
0.3











































w0 w26 w52 w0 w26 w52w106–


























































































Figure 7. Immune cell deconvolution analysis reveals unique changes in intestinal cellular composition in patients responding to HSCT treatment compared to 
anti-TNFα. [A] Cell deconvolution analysis [CIBERSORT] of biopsy samples from healthy non-IBD controls [n = 19] and CD patients before and after treatment 
with anti-TNFα [n = 22, 13 responders] and HSCT [n = 14, 8 responders]. The figure shows the results for naïve B cells [A], resting memory T cells [B], M1 
macrophages [C] and neutrophils [D]. Information on colon biopsy samples from responders to HSCT at week 106 [2 years following HSCT; n = 7] is also included 
in this analysis. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; significant by Mann–Whitney–Wilcoxon test.
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knowledge, this is the first in-depth characterization of the cellular 
and molecular mechanisms leading to remission induced by autolo-
gous HSCT. Transcriptional analysis of the biopsies revealed over 
2000 genes being significantly regulated in remitting patients. This 
signature comprised hundreds of genes that are also markedly regu-
lated by anti-TNF therapy and included cytokine-mediated inflam-
matory pathways, genes expressed by infiltrating immune cells such 
as granulocytes and activated macrophages, as well as tissue remodel-
ling and regenerating pathways that have been extensively described 
to be modulated in response to conventional treatment.30,31 This 
analysis clearly shows that in this group of CD patients [50% of our 
study cohort], HSCT was able to drive mucosal healing associated 
with profound molecular changes characteristic of disease remission.
Remarkably, about 50% of the signature of HSCT-remitters 
was not shared by anti-TNFα remitters. This HSCT-exclusive sig-
nature primarily comprised T-cell-related genes, suggesting changes 
in the mucosal T-cell content and phenotype following HSCT. This 
observation was further confirmed by deconvolution analysis. This 
computational approach looks at whole genome transcriptional 
signatures from complex tissues such as the intestinal lamina pro-
pria to enumerate cell subsets present at different time points. Using 
this approach, we characterized and inferred changes in tissue cell 
composition following HSCT. While achieving endoscopic remis-
sion in response to HSCT or anti-TNFα therapy was associated with 
changes in the neutrophil and M1 macrophage proportions in biop-
sies, changes in other immune cellular subsets, such as naïve B cells 
or certain populations of T cells, were only observed after transplant.
The unique expansion of naïve B cells within the mucosa of 
patients in remission after HSCT closely correlated with the changes 
observed in peripheral blood in these patients, and as mentioned, 
was not observed in response to anti-TNFα treatment. The signifi-
cance of this B-cell expansion is difficult to ascertain. However, based 
on preliminary data on both blood and tissue samples at 2  years 
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Figure 8. T-cell-related gene expression by RNAseq before and after treatment with anti-TNFα and HSCT. Gene expression was determined in intestinal biopsies 
by RNAseq in CD patients treated with anti-TNFα therapy or autologous HSCT. The expression values are normalized and represent log-transformed counts for 
each gene. Dotted lines show the SEM for each gene from the control samples in each cohort. Expression at different time points for endoscopic remitters and 
non-remitters is shown for T-cell-related genes CD3E, CD28 and CD40LG [A]; tissue-resident T cells [TRM] CD69, ITGEA and ITGA1 [B], activated effector T cells 
S1PR1, IL2RA and CTLA4 [C], and neutrophils or the macrophage genes CXCL9, CXCL10 and CD16B [B]. Asterisks mark the statistically significant differences in 
each group for each treatment compared to baseline, by Mann–Whitney–Wilcoxon test; *p > 0.05.
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the enlargement of this compartment following the severe aplasia 
induced by the conditioning protocol.
Potentially more relevant to the mechanism of action at work in 
the transplantation protocol is the significant decrease in the intestinal 
CD4+ memory compartment of patients in remission after HSCT. This 
population did not change to the same extent from anti-TNFα treat-
ment, revealing a mechanism unique to the transplantation protocol. 
Anti-TNFα has been shown to partially modulate the mucosal T-cell 
repertoire, acting primarily on highly expanded clones.32 In fact, in our 
cohort we did see a significant down-regulation of certain T-cell-related 
genes, especially those related to the activated effector compartment. 
Indeed, induction of T-cell apoptosis has been described to take place 
as rapidly as 24 h after anti-TNFα treatment.33,34 While anti-TNFα can 
therefore act on the T-cell infiltrate, the study by Doorenspleet et al. 
showed that a considerable part of the repertoire in the mucosa of CD 
patients persisted regardless of the response to this biological.32
Our data suggest that HSCT achieved a significant reduction in 
total T-cell mucosa content, as seen by the significant down-regula-
tion of genes such as CD3E and CD28. This suggests that transplant 
has a profound effect on the overall T-cell content that is unique 
to the stem cell transplant therapy and is probably induced by the 
ablative treatment. This effect, in contrast to the depletion of T cells 
in the peripheral blood, was not seen in non-responders to HSCT, 
suggesting strongly that depletion of T cells in the mucosa is linked 
to the efficacy of this treatment. One possibility that would need 
further study is that HSCT, but not anti-TNFα, can act on the tissue-
resident T-cell compartment [TRM], which constitutes a predominant 
T-cell subset in healthy mucosal tissues.35 These non-migratory T 
cells are poorly characterized in the context of CD and have been 
described as acquiring CD69 expression [while losing S1PR1 upon 
tissue entering], as well as the integrins αE [CD103] and α1 [ITGA1], 
which only decrease in the HSCT-remitting cohort.
In summary, our study provides the first in-depth description of 
immune cell depletion and reconstitution following immune ablation 
and HSCT in a group of CD patients. While previous studies in other 
autoimmune diseases have suggested that peripheral immune renewal 
might explain the induction of remission, we demonstrate here that this 
change alone does not predict efficacy of HSCT in CD. In contrast, we 
show that remission induced by HSCT, but not by anti-TNFα therapy, 
results in a significant decrease in the mucosal T-cell content, suggesting 
that this represents an important mechanism of HSCT efficacy in CD.
Funding
This work was supported by the Leona and Harry Helmsley Charitable Trust 
grant 2015PG-IBD005, by grant SAF2015-66379-R to AS and JP from the 
Ministerio de Economía y Competitividad, Spain, by Instituto de Salud Carlos 
III, by grant PI17/00513 to ER, by Boehringer Ingelheim and MSD. DB-R, NP 
and ME are supported by the Centro de Investigación Biomédica en Red de 
Enfermedades Hepáticas y Digestivas [CIBERehd].
Conflict of Interest
SV and PB are Boehringer Ingelheim Pharmaceuticals Inc. employees. AS 
has received consultancy fees and grant money from Boehringer Ingelheim 
Pharmaceuticals Inc. JP has received grant money from MSD.
Acknowledgments
We are indebted to the Biobank core facility and Cytomics core facility at 
IDIBAPS for their technical assistance. We thank the Microbiology Laboratory 
at Hospital Clinic, Barcelona, for serum antibody detection. We are grateful 
to Joe Moore for editorial assistance, and Daniel Aguilar for RNAseq analysis 
assistance. English-language assistance was provided by Joe Moore, funded by 
the Leona and Harry Helmsley Charitable Trust.
Author Contributions
AS, ER and JP designed the experiments. AMC and ME performed most of the 
experiments. CE, RC-C and DB-R designed and performed the flow cytometry 
experiments. AM, AL, MR, MCM and ER recruited patients and collected pa-
tient data and samples. SV and PB performed the RNAseq of the anti-TNFα 
cohort data. NP collected and analysed anti-TNFα cohort data. AS and AMC 
analysed all of the data. AMC, AS and MV wrote the manuscript with contri-
butions from JP, ER, MR, LLB and MA. All authors reviewed the manuscript 
before submission.
Transcript Profiling
Blood microarray raw data and biopsy RNAseq data have been deposited 
in NCBI’s Gene Expression Omnibus and are accessible through GEO Series 
accession number GSE100922 for blood and GSE115390 for biopsy data.
Supplementary Data
Supplementary data are available at ECCO-JCC online.
References
 1. Hawkey CJ, Allez M, Clark MM, et al. Autologous hematopoetic stem cell 
transplantation for refractory Crohn disease: a randomized clinical trial. 
JAMA 2015;314:2524–34.
 2. Jauregui-Amezaga A, Rovira M, Marín P, et al. Improving safety of autolo-
gous haematopoietic stem cell transplantation in patients with Crohn’s 
disease. Gut 2016;65:1456–62.
 3. Saccardi  R, Kozak  T, Bocelli-Tyndall  C, et  al.; Autoimmune Diseases 
Working Party of EBMT. Autologous stem cell transplantation for pro-
gressive multiple sclerosis: update of the European Group for Blood and 
Marrow Transplantation autoimmune diseases working party database. 
Mult Scler 2006;12:814–23.
 4. Sormani  MP, Muraro  PA, Schiavetti  I, et  al. Autologous hematopoietic 
stem cell transplantation in multiple sclerosis: a meta-analysis. Neurology 
2017;88:2115–22.
 5. Alchi B, Jayne D, Labopin M, et al.; EBMT Autoimmune Disease Working 
Party members. Autologous haematopoietic stem cell transplantation for 
systemic lupus erythematosus: data from the European Group for Blood 
and Marrow Transplantation registry. Lupus 2013;22:245–53.
 6. Abinun M, Flood TJ, Cant AJ, et al. Autologous T cell depleted haema-
topoietic stem cell transplantation in children with severe juvenile idi-
opathic arthritis in the UK (2000-2007). Mol Immunol 2009;47:46–51.
 7. Snowden JA, Passweg J, Moore JJ, et al. Autologous hemopoietic stem cell 
transplantation in severe rheumatoid arthritis: a report from the EBMT 
and ABMTR. J Rheumatol 2004;31:482–8.
 8. Lopez-Garcia A, Rovira M, Jauregui-Amezaga A, et al. Autologous hemat-
opoietic stem cell transplantation for refractory Crohn’s disease: efficacy 
in a single-centre cohort. J Crohn’s Colitis 2017;11:1161–8.
 9. Lindsay JO, Allez M, Clark M, et al.; ASTIC trial group; European Society 
for Blood and Marrow Transplantation Autoimmune Disease Working 
Party; European Crohn’s and Colitis Organisation. Autologous stem-
cell transplantation in treatment-refractory Crohn’s disease: an analy-
sis of pooled data from the ASTIC trial. Lancet Gastroenterol Hepatol 
2017;2:399–406.
 10. Feagan  BG, Sandborn  WJ, Gasink  C, et  al.; UNITI–IM-UNITI Study 
Group. Ustekinumab as induction and maintenance therapy for Crohn’s 
disease. N Engl J Med 2016;375:1946–60.
 11. Alexander  T, Thiel  A, Rosen  O, et  al. Depletion of autoreactive immu-
nologic memory followed by autologous hematopoietic stem cell trans-
plantation in patients with refractory SLE induces long-term remission 






/ecco-jcc/article-abstract/13/5/634/5232131 by guest on 31 January 2020
through de novo generation of a juvenile and tolerant immune system. 
Blood 2009;113:214–23.
 12. Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell sub-
sets from tissue expression profiles. Nat Methods 2015;12:453–7.
 13. Main J, McKenzie H, Yeaman GR, et al. Antibody to Saccharomyces cer-
evisiae (bakers’ yeast) in Crohn’s disease. BMJ 1988;297:1105–6.
 14. Calderón-Gómez E, Bassolas-Molina H, Mora-Buch R, et al. Commensal-
specific CD4(+) cells from patients with Crohn’s disease have a T-helper 17 
inflammatory profile. Gastroenterology 2016;151:489–500.e3.
 15. Schoepfer  AM, Schaffer  T, Mueller  S, et  al. Phenotypic associations of 
Crohn’s disease with antibodies to flagellins A4-Fla2 and Fla-X, ASCA, 
p-ANCA, PAB, and NOD2 mutations in a Swiss Cohort. Inflamm Bowel 
Dis 2009;15:1358–67.
 16. Muraro PA, Douek DC. Renewing the T cell repertoire to arrest autoim-
mune aggression. Trends Immunol 2006;27:61–7.
 17. Pockley AG, Lindsay JO, Foulds GA, et al. Immune reconstitution after 
autologous hematopoietic stem cell transplantation in Crohn’s disease: 
current status and future directions. a review on behalf of the EBMT auto-
immune diseases working party and the autologous stem cell transplanta-
tion in refractory CD-low intensity therapy evaluation study investigators. 
Front Immunol 2018;9:646.
 18. Szodoray P, Varoczy L, Papp G, et al. Immunological reconstitution after 
autologous stem cell transplantation in patients with refractory systemic 
autoimmune diseases. Scand J Rheumatol 2012;41:110–5.
 19. Muraro PA, Douek DC, Packer A, et al. Thymic output generates a new 
and diverse TCR repertoire after autologous stem cell transplantation in 
multiple sclerosis patients. J Exp Med 2005;201:805–16.
 20. Thiel A, Alexander T, Schmidt CA, et al. Direct assessment of thymic reactiva-
tion after autologous stem cell transplantation. Acta Haematol 2008;119:22–7.
 21. Farge D, Henegar C, Carmagnat M, et al. Analysis of immune reconstitu-
tion after autologous bone marrow transplantation in systemic sclerosis. 
Arthritis Rheum 2005;52:1555–63.
 22. de Kleer I, Vastert B, Klein M, et al. Autologous stem cell transplantation 
for autoimmunity induces immunologic self-tolerance by reprogramming 
autoreactive T cells and restoring the CD4+CD25+ immune regulatory 
network. Blood 2006;107:1696–702.
 23. Abrahamsson  SV, Angelini  DF, Dubinsky  AN, et  al. Non-myeloablative 
autologous haematopoietic stem cell transplantation expands regulatory 
cells and depletes IL-17 producing mucosal-associated invariant T cells in 
multiple sclerosis. Brain 2013;136:2888–903.
 24. Clerici M, Cassinotti A, Onida F, et al. Immunomodulatory effects of unse-
lected haematopoietic stem cells autotransplantation in refractory Crohn’s 
disease. Dig Liver Dis 2011;43:946–52.
 25. Hakim  FT, Cepeda  R, Kaimei  S, et  al. Constraints on CD4 recovery 
postchemotherapy in adults: thymic insufficiency and apoptotic decline of 
expanded peripheral CD4 cells. Blood 1997;90:3789–98.
 26. Cull G, Hall D, Fabis-Pedrini MJ, et al. Lymphocyte reconstitution follow-
ing autologous stem cell transplantation for progressive MS. Mult Scler J 
Exp Transl Clin 2017;3:2055217317700167.
 27. Mackall CL, Fleisher TA, Brown MR, et al. Distinctions between CD8+ 
and CD4+ T-cell regenerative pathways result in prolonged T-cell subset 
imbalance after intensive chemotherapy. Blood 1997;89:3700–7.
 28. Muraro  PA, Robins  H, Malhotra  S, et  al. T cell repertoire following 
autologous stem cell transplantation for multiple sclerosis. J Clin Invest 
2014;124:1168–72.
 29. Mackall CL, Stein D, Fleisher TA, et al. Prolonged CD4 depletion after 
sequential autologous peripheral blood progenitor cell infusions in chil-
dren and young adults. Blood 2000;96:754–62.
 30. Leal RF, Planell N, Kajekar R, et al. Identification of inflammatory media-
tors in patients with Crohn’s disease unresponsive to anti-TNFα therapy. 
Gut 2015;64:233–42.
 31. Arijs I, De Hertogh G, Machiels K, et al. Mucosal gene expression of cell 
adhesion molecules, chemokines, and chemokine receptors in patients 
with inflammatory bowel disease before and after infliximab treatment. 
Am J Gastroenterol 2011;106:748–61.
 32. Doorenspleet ME, Westera L, Peters CP, et al. Profoundly expanded T-cell 
clones in the inflamed and uninflamed intestine of patients with Crohn’s 
disease. J Crohns Colitis 2017;11:831–9.
 33. Van den Brande JM, Koehler TC, Zelinkova Z, et al. Prediction of antitu-
mour necrosis factor clinical efficacy by real-time visualisation of apopto-
sis in patients with Crohn’s disease. Gut 2007;56:509–17.
 34. ten  Hove  T, van  Montfrans  C, Peppelenbosch  MP, van  Deventer  SJ. 
Infliximab treatment induces apoptosis of lamina propria T lymphocytes 
in Crohn’s disease. Gut 2002;50:206–11.
 35. Thome JJ, Farber DL. Emerging concepts in tissue-resident T cells: lessons 
from humans. Trends Immunol 2015;36:428–35.






/ecco-jcc/article-abstract/13/5/634/5232131 by guest on 31 January 2020
